DSM Nutritional Products Ltd. and Evonik Nutrition & Care GmbH to develop algae-based omega-3 fatty acids for animal nutrition
DSM Nutritional Products Ltd. (Kaiseraugst, Switzerland) and Evonik Nutrition & Care GmbH (Essen, Germany) today announced they have entered into a joint development agreement for algae-based omega-3 fatty acid products for animal nutrition, in particular in aquaculture and pet food applications. The aim is to meet the increasing demand for omega-3 fatty acids by harnessing naturally occurring marine algae using sustainable, biotechnological processes based on natural, non-marine resources.
Under the agreement, the companies will jointly work on the development of products and explore opportunities for commercialization. The competencies that DSM and Evonik bring to the development partnership complement each other: DSM has expertise in the cultivation of marine organisms and long-established biotechnology capabilities in development and operations, whilst Evonik’s focus for decades has been on industrial amino acid biotechnology executing large-volume fermentation processes.
The envisioned algae-based omega-3 fatty acid products will be high value, natural and sustainable alternatives to fish oil, whose supply is finite. This will help the animal nutrition industry keep up with increasing demand without endangering fish stocks and will contribute to healthy and sustainable animal nutrition. Just like humans, animals also need their daily intake of essential, long-chain polyunsaturated fatty acids in their diet to ensure healthy growth. Until now, these fatty acids have been added to aquaculture feed almost exclusively from marine sources such as fish oil and fishmeal. By using algae, DSM and Evonik are looking to contribute to a more sustainable aquaculture industry.
DSM and Evonik expect that in Q4 2015 they will be able to report the first results of the algae-based omega-3 fatty acid product development.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around €4.2 billion in 2014.
DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
Forward-looking statements DSM
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
Veramaris is a 50:50 joint venture of DSM and Evonik for the production of the omega-3 fatty acids EPA and DHA from natural marine algae. Located in Delft, the Netherlands, Veramaris was launched in 2018, because its parent companies shared a vision: to conserve marine life by using a resource the ocean provides – natural marine microalgae. Producing an algal oil rich in the two essential omega-3 fatty acids EPA and DHA through large-scale fermentation at its facility in Blair, Nebraska, USA, Veramaris enables partners along the value chain to become independent from wild-caught fish and meet the growing demand for animal protein responsibly.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future or the use of products, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Veramaris V.O.F. does not assume an obligation to update the forecasts, expectations or statements contained in this release. The English language version of the press release prevails.